Page last updated: 2024-10-22

amantadine and Psychoses

amantadine has been researched along with Psychoses in 18 studies

amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source

Research Excerpts

ExcerptRelevanceReference
"Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])."9.16Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012)
" Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7."9.09Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001)
"Outpatients with schizophrenia or schizoaffective disorder (DSM-IV-TR criteria) were randomly assigned to olanzapine alone (n = 50), olanzapine plus algorithm A (olanzapine + A [amantadine 200 mg/d with possible switches to metformin 1,000-1,500 mg/d and then to zonisamide 100-400 mg/d; n = 76]), or olanzapine plus algorithm B (olanzapine + B [metformin 1,000-1,500 mg/d with possible switches to amantadine 200 mg/d and then to zonisamide 100-400 mg/d; n = 73])."5.16Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. ( Case, M; Hoffmann, VP; Jacobson, JG, 2012)
" Amantadine (100-300 mg/day) was started in 12 patients having a mean weight gain of 7."5.09Effect of amantadine on weight gain during olanzapine treatment. ( Deberdt, W; Floris, M; Lejeune, J, 2001)
"Amantadine, which was originally developed as an antiviral medication, functions as a dopamine agonist in the central nervous system and consequently is utilized in the treatment of Parkinson disease, drug-induced extrapyramidal reactions, and neuroleptic malignant syndrome."3.85The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. ( Fox, J; Fryml, LD; Pelic, CG; Revuelta, GJ; Robert, S; Sahlem, G; Short, EB; Williams, KR, 2017)
"To investigate the association of illusions/hallucinations and plasma CRP levels in PD patients without symptomatic infections."1.40Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study. ( Hayashi, R; Kohsaka, M; Oeda, T; Sawada, H; Sudoh, S; Sugiyama, H; Tomita, S; Umemura, A; Yamamoto, K, 2014)
"Pergolide was increased to 8."1.33High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. ( Hundemer, HP; Oehlwein, C; Polzer, U; Schwarz, J; Storch, A; Trenkwalder, C; Winkelmann, J, 2005)
" In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly."1.25Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19905 (27.78)18.7374
1990's3 (16.67)18.2507
2000's4 (22.22)29.6817
2010's4 (22.22)24.3611
2020's2 (11.11)2.80

Authors

AuthorsStudies
Tatar, D2
Świerzy, K2
Błachut, M2
Badura Brzoza, K2
Zaydlin, M1
Bernal, JA1
Bez, Y1
Coffey, BJ1
Fryml, LD1
Williams, KR1
Pelic, CG1
Fox, J1
Sahlem, G1
Robert, S1
Revuelta, GJ1
Short, EB1
Sawada, H1
Oeda, T1
Umemura, A1
Tomita, S1
Hayashi, R1
Kohsaka, M1
Yamamoto, K1
Sudoh, S1
Sugiyama, H1
Hoffmann, VP1
Case, M1
Jacobson, JG1
de Lucena, DF1
Pinto, JP1
Hallak, JE1
Crippa, JA1
Gama, CS1
Bahk, WM1
Lee, KU1
Chae, JH1
Pae, CU1
Jun, T1
Kim, KS1
Storch, A1
Trenkwalder, C1
Oehlwein, C1
Winkelmann, J1
Polzer, U1
Hundemer, HP1
Schwarz, J1
Visanji, NP1
Gomez-Ramirez, J1
Johnston, TH1
Pires, D1
Voon, V1
Brotchie, JM1
Fox, SH1
Danielczyk, W1
Freudenreich, O1
McEvoy, JP1
Northoff, G1
Lins, H1
Böker, H1
Danos, P1
Bogerts, B1
Floris, M1
Lejeune, J1
Deberdt, W1
Eisdorfer, C1
Dolezalová, B1
Vacek, J1
Sczesni, B1
Becker, H1
Schröder, J1
Bittkau, S1
von Baumgarten, F1
Truong, DD1
Przuntek, H1
Castaigne, P1
Laplane, D1
Autret, A1
Ferraris, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia[NCT00401973]Phase 3199 participants (Actual)Interventional2006-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline to Endpoint in Weight

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

Interventionkilograms (Least Squares Mean)
Olanzapine2.76
Olanzapine + Amantadine2.40
Olanzapine + Metformin0.65

Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score

The BPRS is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Each item is rated on a scale from 1 (symptom not present) to 7 (symptom extremely severe). The BPRS total score ranges from 18 to 126. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline
Olanzapine48.24-13.89
Olanzapine + Amantadine45.90-9.90
Olanzapine + Metformin47.00-9.72

Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S)

Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline
Olanzapine4.06-0.98
Olanzapine + Amantadine4.03-0.72
Olanzapine + Metformin4.00-0.79

Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline
Olanzapine12.76-6.39
Olanzapine + Amantadine14.22-4.12
Olanzapine + Metformin15.40-4.36

Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks

To understand the drivers of weight gain as indicated by the correlation between weight changes and changes in the Eating Inventory (EI) and Food Craving Inventory (FCI). The EI is a 51-item inventory that measures dietary restraint, disinhibition, and perceived hunger. The FCI is a 28-item instrument measuring the frequency over the past month of general cravings and cravings for specific types of foods, namely: high fats, sweets, carbohydrates/starches, and fast-food fats. Correlations were computed on the combined treatment groups. (NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,
Interventioncorrelation (Number)
EI: DisinhibitionEI: Cognitive RestraintEI: HungerFCI: Carbohydrates/Starches (N=186, N=141)FCI: Fast Food Fats (N=188, N=140)FCI: High Fats (N=186, N=138)FCI: Sweets (N=187, N=140)FCI: Total Score (N=184, N=137)
2 Weeks-0.034-0.273-0.1500.013-0.0190.0510.0220.039
22 Weeks0.285-0.0380.148-0.0640.0470.043-0.008-0.000

Mean Change From Baseline to Endpoint in Fasting Glucose

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimole per Liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine5.320.26
Olanzapine + Amantadine5.250.10
Olanzapine + Metformin5.280.01

Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimole per liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine1.25-0.00
Olanzapine + Amantadine1.26-0.11
Olanzapine + Metformin1.22-0.08

Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimole per Liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine3.020.16
Olanzapine + Amantadine3.06-0.04
Olanzapine + Metformin2.91-0.02

Mean Change From Baseline to Endpoint in Fasting Total Cholesterol

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimole per Liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine5.010.36
Olanzapine + Amantadine5.030.01
Olanzapine + Metformin4.91-0.08

Mean Change From Baseline to Endpoint in Fasting Triglycerides

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionmillimoles per Liter (mmol/L) (Mean)
BaselineChange from Baseline
Olanzapine1.580.33
Olanzapine + Amantadine1.610.35
Olanzapine + Metformin1.680.06

Mean Change From Baseline to Endpoint in Hemoglobin A1c

(NCT00401973)
Timeframe: Baseline to endpoint (22 weeks)

,,
Interventionpercent hemoglobin A1c (Mean)
BaselineChange from Baseline
Olanzapine5.510.09
Olanzapine + Amantadine5.480.10
Olanzapine + Metformin5.53-0.03

Trials

4 trials available for amantadine and Psychoses

ArticleYear
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:2

    Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Pro

2012
Open label study of the effect of amantadine on weight gain induced by olanzapine.
    Psychiatry and clinical neurosciences, 2004, Volume: 58, Issue:2

    Topics: Adult; Amantadine; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body We

2004
Effect of amantadine on weight gain during olanzapine treatment.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2001, Volume: 11, Issue:2

    Topics: Adult; Amantadine; Antipsychotic Agents; Benzodiazepines; Dopamine Agents; Female; Humans; Male; Ola

2001
[Clinical study of the psychostimulant action of amantadine].
    La Nouvelle presse medicale, 1974, Jun-29, Volume: 3, Issue:26

    Topics: Amantadine; Antidepressive Agents; Attention; Central Nervous System; Clinical Trials as Topic; Coma

1974

Other Studies

14 other studies available for amantadine and Psychoses

ArticleYear
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report.
    International journal of environmental research and public health, 2022, 11-27, Volume: 19, Issue:23

    Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2

2022
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report.
    International journal of environmental research and public health, 2022, 11-27, Volume: 19, Issue:23

    Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2

2022
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report.
    International journal of environmental research and public health, 2022, 11-27, Volume: 19, Issue:23

    Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2

2022
Psychotic Disorders in the Course of SARS-CoV-2 Infection or Uncomplicated Amantadine Treatment?-Case Report.
    International journal of environmental research and public health, 2022, 11-27, Volume: 19, Issue:23

    Topics: Amantadine; COVID-19; Humans; Psychotic Disorders; SARS-CoV-2

2022
Improved Treatment Outcome with Haloperidol Decanoate and Amantadine in an Adolescent with Schizoaffective Disorder.
    Journal of child and adolescent psychopharmacology, 2023, Volume: 33, Issue:8

    Topics: Adolescent; Amantadine; Antipsychotic Agents; Haloperidol; Humans; Psychotic Disorders; Treatment Ou

2023
The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.
    Journal of psychiatric practice, 2017, Volume: 23, Issue:3

    Topics: Aged; Amantadine; Catatonia; Delirium; Dopamine Agents; Electroconvulsive Therapy; Humans; Male; Mid

2017
Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Amantadine; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Delusions; Dopamine A

2014
Short-term treatment of catatonia with amantadine in schizophrenia and schizoaffective disorder.
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:4

    Topics: Adult; Amantadine; Catatonia; Female; Humans; Male; Psychotic Disorders; Receptors, N-Methyl-D-Aspar

2012
High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Parkinsonism & related disorders, 2005, Volume: 11, Issue:6

    Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combin

2005
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:11

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine

2006
[Crises in the course of Parkinson's disease].
    Wiener medizinische Wochenschrift (1946), 1980, Feb-29, Volume: 130, Issue:4

    Topics: Aged; Amantadine; Bromocriptine; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson

1980
Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics.
    The Journal of clinical psychiatry, 1995, Volume: 56, Issue:4

    Topics: Adult; Amantadine; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched

1995
Therapeutic efficacy of N-methyl D-aspartate antagonist amantadine in febrile catatonia.
    Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:5

    Topics: Adult; Amantadine; Bipolar Disorder; Catatonia; Dopamine Agents; Excitatory Amino Acid Agonists; Fev

1999
Observations on the psychopharmacology of the aged.
    Journal of the American Geriatrics Society, 1975, Volume: 23, Issue:2

    Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone

1975
[Modern antiparkinsonics (L-dopa and amantadine) and presentday psychiatry (author's transl)].
    Ceskoslovenska psychiatrie, 1976, Volume: 72, Issue:6

    Topics: Amantadine; Humans; Levodopa; Mental Disorders; Parkinson Disease, Secondary; Psychotic Disorders

1976
[Diagnostic and therapeutic aspects of neuroleptic malignant syndrome based on 12 cases].
    Wiener klinische Wochenschrift, 1991, Volume: 103, Issue:1

    Topics: Adult; Amantadine; Antipsychotic Agents; Bromocriptine; Dantrolene; Depressive Disorder; Diazepam; D

1991
[Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa].
    Minerva medica, 1971, Oct-31, Volume: 62, Issue:82

    Topics: Affective Symptoms; Amantadine; Dihydroxyphenylalanine; Humans; Parkinson Disease; Psychotic Disorde

1971